Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
Open Access
- 15 November 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 163 (10) , 5211-5218
- https://doi.org/10.4049/jimmunol.163.10.5211
Abstract
This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise nonresponding animals. Elimination of CD25-expressing T cells, which constitute 5–10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them. The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4−8− cytotoxic cells akin to NK cells. Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepared from tumor-unsensitized normal mice led to spontaneous generation of similar CD4−8− cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation. In this culture, self-reactive CD25−4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amounts of IL-2. The IL-2 thus produced appeared to be responsible for the generation of CD4−8− NK cells as lymphokine-activated killer cells, because direct addition of an equivalent amount of IL-2 to the culture of CD4−8− cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4−8− cells with CD25−4+ T cells from IL-2-deficient mice did not. Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunological unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones. This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.Keywords
This publication has 54 references indexed in Scilit:
- T Cell-Mediated Maintenance of Natural Self-Tolerance: its Breakdown as a Possible Cause of Various Autoimmune DiseasesJournal of Autoimmunity, 1996
- Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.The Journal of Experimental Medicine, 1996
- Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.The Journal of Experimental Medicine, 1994
- CD3+CD16+NK1.1+B220+ large granular lymphocytes arise from both alpha-beta TCR+CD4-CD8- and gamma-delta TCR+CD4-CD8- cells.The Journal of Experimental Medicine, 1994
- Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ GenesScience, 1993
- Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cellsClinical Immunology and Immunopathology, 1990
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cellsNature, 1985
- Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia moleculesThe Journal of Experimental Medicine, 1981